These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30300295)

  • 1. Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations: An Observational Study Including 8,288 Patients.
    Tveito M; Smith RL; Molden E; Haslemo T; Refsum H; Hartberg C; Correll CU; Høiseth G
    J Clin Psychopharmacol; 2018 Dec; 38(6):570-576. PubMed ID: 30300295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.
    Tveito M; Smith RL; Høiseth G; Molden E
    J Clin Psychopharmacol; 2019; 39(6):561-566. PubMed ID: 31688390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients.
    Tveito M; Smith RL; Molden E; Høiseth G
    Eur J Clin Pharmacol; 2021 Feb; 77(2):215-221. PubMed ID: 33000414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
    Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
    Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulations-an observational study using blood samples from 1223 patients.
    Tveito M; Høiseth G; Haslemo T; Molden E; Smith RL
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1201-1208. PubMed ID: 33616704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of risperidone in different application forms - Comparing long-acting injectable and oral formulations.
    Schoretsanitis G; de Leon J; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):130-137. PubMed ID: 29153926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.
    Hill AL; Sun B; McDonnell DP
    Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):216-22. PubMed ID: 23428782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraindividual and Interindividual Variability of Olanzapine Trough Concentrations in Patients Treated With the Long-Acting Injectable Formulation.
    Baldelli S; Mauri MC; Di Pace C; Paletta S; Reggiori A; Rovera C; Clementi E; Cattaneo D
    J Clin Psychopharmacol; 2018 Aug; 38(4):365-369. PubMed ID: 29912794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive Outcomes in Nonacute Patients With Schizophrenia Treated With Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics.
    Petric PS; Teodorescu A; Miron AA; Manea MC; Ifteni P
    Am J Ther; 2024 May-Jun 01; 31(3):e219-e228. PubMed ID: 38691662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.
    Detke HC; Weiden PJ; Llorca PM; Choukour M; Watson SB; Brunner E; Ascher-Svanum H
    J Clin Psychopharmacol; 2014 Aug; 34(4):426-34. PubMed ID: 24781441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching.
    Detke HC; Zhao F; Garhyan P; Carlson J; McDonnell D
    Int Clin Psychopharmacol; 2011 Jan; 26(1):35-42. PubMed ID: 20948432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.
    Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP
    BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
    Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
    Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
    Graffino M; Montemagni C; Mingrone C; Rocca P
    Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
    Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
    J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.
    Vieta E; Montgomery S; Sulaiman AH; Cordoba R; Huberlant B; Martinez L; Schreiner A
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):825-35. PubMed ID: 22503488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explicit review of risperidone long-acting injection prescribing practice.
    Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
    J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
    Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
    Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.